Positive developments in the late-stage trials for Merck's Keytruda immunotherapy lung cancer treatment led the company's stock to spike nearly 4 percent April 9, according to Fortune.
The KEYNOTE-o42 trial demonstrated that taking Keytruda was more effective in treating lung cancer than chemotherapy, and further findings could mean that patients can skip chemo treatment altogether. The recent stock gain represents almost $5.75 billion in market value.
Keytruda earned Merck more than $3.8 billion in sales in 2017.